Eyevance Pharmaceuticals was born out of a desire to revolutionize the eye care industry. Co-Founders Jerry St. Peter and Jason Werner had worked together in the ophthalmic space for many years leading up to their life-changing decision to form Eyevance. They noticed a therapeutic segment of the industry was largely underserved and immediately saw an opportunity to not only occupy the space, but to step up and lead it.
Jerry and Jason’s combined entrepreneurial spirits, industry experience and know-how, innovative mindsets, and drive to win made venturing out on their own a no-brainer. In September 2017, their vision was realized — and the journey had just begun.
Due to their relentless efforts and unrivaled passion, Eyevance quickly gained momentum, and is still going strong. We are proud to have built a culture much like Jerry and Jason themselves, centered around entrepreneurship, hard work, and tenacity. Consequently, the Eyevance team has been unstoppable.
Eyevance was founded on the concept of thinking, acting, and doing differently. We see opportunities where others don’t. We think outside the box, problem solving and innovating in unconventional ways. Everything we do centers around our customers.
We’re setting a new bar, and we’re setting it high. We believe in choosing every day to be extraordinary. We believe in living with intention and purpose and making a difference in people’s lives.
We believe it’s time for an eye care revolution.
September 1, 2017
Eyevance formation by Co-Founders Jerry St. Peter and Jason Werner; initial financing
First business development deal – licensed ZERVIATE™ from Nicox
Acquired first innovative development stage program – VISOVANQ™ from Kurobe
Hired Chief Scientific Officer, Mark C. Jasek, PhD
Hired Chief Financial Officer, Wes Brazell
Acquired FRESHKOTE® Preservative Free (PF) Tear Lubricant from Focus Laboratories
Acquired NEXAGON® – an innovative, rare disease ophthalmic program – from OcuNexus Therapeutics
Acquired three non-disclosed, FDA approved NDAs
Acquired TOBRADEX® ST and NATACYN® from Novartis; completed finance transaction to fully fund Eyevance
U.S. launch of TOBRADEX® ST
U.S. launch of ZERVIATE™